Oncology

Combination immunotherapy shows limited efficacy in sarcoma

Although combination immunotherapy (nivolumab + ipilimumab) appears to be effective in certain sarcoma subtypes, it is ineffective in others, according to a study. The Phase 2 study investigated the efficacy of nivolumab alone and in combination with ipilimumab in 66 patients with advanced gastrointestinal stromal tumor (GIST), undifferentiated pleomorphic sarcoma...